Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
This article was originally published in The Gray Sheet
Executive Summary
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting
You may also be interested in...
Consultants Tapped To Help FDA With Post-Approval Study Mandates
FDA has hired outside help to improve the process for imposing clinical study requirements after a company's product is approved for marketing
Consultants Tapped To Help FDA With Post-Approval Study Mandates
FDA has hired outside help to improve the process for imposing clinical study requirements after a company's product is approved for marketing
FDA Premarket Activity Safe From Current Political Storm – Ex Chief Counsel
Current public pressure on the FDA in the wake of a string of high-profile safety problems for both drugs and devices will not make the agency more restrained in approving premarket applications, according to one former top FDA official